

AMENDMENTS TO THE CLAIMS

1-4. (Canceled)

5. (Previously Presented) An isolated polypeptide comprising the full length of amino acid sequence of SEQ ID NO:18.

6. (Currently Amended) An isolated polypeptide according to claim 5, wherein the polypeptide is recombinantly produced comprising a recombinant protein generated in an isolated host cell in which the DNA encoding the full length of an amino acid sequence of SEQ ID NO:18 is introduced.

7-13. (Canceled)

14. (Currently Amended) A vascular proliferation screening and differentiation control factor polypeptide binding kit comprising the polypeptide according to claim 5 or 6 and a control compound based on a protein-protein interaction detection system or an agonist, or an antagonist, or an in vivo ligand detection system.

15-18. (Canceled)

19. (Currently Amended) A composition comprising the polypeptide according to claim 5 or 6 as an active ingredient, [[;]] and a pharmaceutically acceptable carrier therefore.

20. (Previously Presented) A method of inhibiting angiogenesis which comprises contacting a vascular cell with an isolated polypeptide of claim 5 or 6.